ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Medicenna Therapeutics Corporation (QB)

Medicenna Therapeutics Corporation (QB) (MDNAF)

2.07
0.00
(0.00%)
Closed June 03 4:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.07
Bid
2.13
Ask
2.24
Volume
300
0.00 Day's Range 0.00
0.158 52 Week Range 2.20
Market Cap
Previous Close
2.07
Open
-
Last Trade Time
08:26:22
Financial Volume
-
VWAP
-
Average Volume (3m)
131,279
Shares Outstanding
69,637,469
Dividend Yield
-
PE Ratio
-19.75
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-10.05M

About Medicenna Therapeutics Corporation (QB)

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Toronto, Ontario, Can
Founded
1970
Medicenna Therapeutics Corporation (QB) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QB) was $2.07. Over the last year, Medicenna Therapeutics (QB) shares have traded in a share price range of $ 0.158 to $ 2.20.

Medicenna Therapeutics (QB) currently has 69,637,469 shares outstanding. The market capitalization of Medicenna Therapeutics (QB) is $198.47 million. Medicenna Therapeutics (QB) has a price to earnings ratio (PE ratio) of -19.75.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3218.28571428571.752.21.6421877871.97390085CS
40.3520.34883720931.722.21.611204981.88660924CS
121.229146.1355529130.8412.20.83281312791.51448099CS
261.722494.8275862070.3482.20.28391080281.11202966CS
521.9061162.195121950.1642.20.1581158950.95440908CS
1561.9061162.195121950.1642.20.1581158950.95440908CS
2601.4531235.5487112980.61695.320.158755251.75398087CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.3828
(0.00%)
541
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.7907
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.80
(0.00%)
1.4k
AACIArmada Acquisition Corporation I
$ 11.55
(0.00%)
26
AACGATA Creativity Global
$ 0.9485
(0.00%)
19
AAGRAfrican Agriculture Holdings Inc
$ 0.3828
(0.00%)
541
AADRAdvisorShares Dorsey Wright ADR ETF
$ 64.7907
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.80
(0.00%)
1.4k
AACIArmada Acquisition Corporation I
$ 11.55
(0.00%)
26
AACGATA Creativity Global
$ 0.9485
(0.00%)
19
CRKNCrown Electrokinetics Corporation
$ 0.10
(0.00%)
93.97M
FFIEFaraday Future Intelligent Electric Inc
$ 0.5834
(0.00%)
58.36M
BPTHBio Path Holdings Inc
$ 2.06
(0.00%)
14.33M
SLNASelina Hospitality PLC
$ 0.0943
(0.00%)
9.78M
HLTHCue Health Inc
$ 0.0676
(0.00%)
8.8M

MDNAF Discussion

View Posts
2H2 2H2 3 days ago
And more awesome results. 20x bagger here soon? Pc needs a new top line therapy, guess who?
πŸ‘οΈ0
2H2 2H2 1 month ago
MDNAF is a presenter at ASCO. Huge news!
πŸ‘οΈ0
2H2 2H2 2 months ago
Great presentation at ASCO
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
πŸ‘οΈ0
2H2 2H2 3 months ago
Relishing soon. This will be 10x current value this year
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
πŸ‘οΈ0
2H2 2H2 3 months ago
Getting legs here. Train leaving.
πŸ‘οΈ0
axelvento axelvento 7 months ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
πŸ‘οΈ0
Renee Renee 7 months ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
MDNA NEW 52 week low
πŸ‘οΈ0
Investopotia Investopotia 2 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
πŸ‘οΈ0
EagleD EagleD 3 years ago
Going much higher. Double digits in a few months
πŸ‘οΈ0
EagleD EagleD 3 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
πŸ‘οΈ0
EagleD EagleD 4 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
πŸ‘οΈ0
EagleD EagleD 4 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
πŸ‘οΈ0
Renee Renee 4 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
πŸ‘οΈ0
tykundegex tykundegex 5 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
πŸ‘οΈ0
BioSpecialist BioSpecialist 7 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock